By Adriano Marchese

 

Eli Lilly & Co. said Wednesday that it has submitted new data in its request for an emergency authorization from the Food and Drug Administration for its drug bamlanivimab to treat mild cases of Covid-19.

The Indianapolis-based company said that it has included in the submission data published by the New England Journal of Medicine from a Phase 2 study on the drug.

"The publication of these data in a peer-reviewed journal adds to the growing body of evidence for the potential utility for neutralizing antibodies as therapeutics for people recently diagnosed with mild to moderate COVID-19, particularly high-risk patients," said Ajay Nirula, vice president of immunology and co-first author of the study.

The Phase 2 study was designed to assess the efficacy and safety of bamlanivimab alone for the treatment of symptomatic Covid-19 in the outpatient setting, the company said.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

October 28, 2020 17:58 ET (21:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Eli Lilly Charts.